The Scientist

» FDA and culture

Most Recent

image: Meeting of the Minds

Meeting of the Minds

By | July 1, 2012

New changes at The Scientist will ensure that we continue to showcase the best and brightest ideas in the life sciences.

1 Comment

image: All’s Not Fair in Science and Publishing

All’s Not Fair in Science and Publishing

By | July 1, 2012

False credit for scientific discoveries threatens the success and pace of research.

72 Comments

image: A Placebo for Schizophrenia?

A Placebo for Schizophrenia?

By | June 26, 2012

The placebo effect in clinical trials of the mental disorder has increased over the past decade.

1 Comment

image: NIH Tackles Racism

NIH Tackles Racism

By | June 25, 2012

An advisory committee urges the federal funding agency to take steps to counter racial bias in the granting process.

2 Comments

image: A Plea to the FDA

A Plea to the FDA

By | June 21, 2012

Protesters crash the BIO conference to protest the delayed approval of a breast cancer drug.

2 Comments

image: New FDA Review Process Debated

New FDA Review Process Debated

By | June 20, 2012

Industry experts discuss the agency’s plans to make the drug approval process more transparent.

0 Comments

image: UK Gov’t Supports Open Access Plan

UK Gov’t Supports Open Access Plan

By | June 19, 2012

The UK government releases its recommendation that open access be “the main vehicle for the publication of research,” though it warns of the costs that could entail.

0 Comments

image: Opinion: What’s Wrong with COI?

Opinion: What’s Wrong with COI?

By | June 12, 2012

Financial “conflicts of interest” should not be so quickly condemned. Industry relationships are unequivocally beneficial.

0 Comments

image: @Pharma Branching Out

@Pharma Branching Out

By | June 11, 2012

More than half of pharmaceutical companies on Twitter use more than one handle.

0 Comments

image: FDA OKs Early Stage Trials

FDA OKs Early Stage Trials

By | June 5, 2012

The regulatory agency will allow early-stage breast cancer patients to try experimental drugs previously reserved for those with advanced disease.

1 Comment

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. Does Productivity Diminish Research Quality?
  3. How Plants Evolved Different Ways to Make Caffeine
  4. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

RayBiotech